Shares of Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) traded down 4.9% during mid-day trading on Wednesday . The company traded as low as $4.44 and last traded at $4.70. 8,527 shares traded hands during mid-day trading, a decline of 16% from the average session volume of 10,173 shares. The stock had previously closed at $4.94.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and set a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.
Get Our Latest Stock Report on Genenta Science
Genenta Science Stock Down 4.9 %
The firm's 50 day moving average is $4.80 and its two-hundred day moving average is $4.08.
Hedge Funds Weigh In On Genenta Science
A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund purchased 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science as of its most recent filing with the SEC. Institutional investors own 15.13% of the company's stock.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
